StreetAlpha.app
Home › Stocks › GPCR

Structure Therapeutics Inc. (GPCR)

Healthcare
$18.17
▼ −2.15%
LAST CLOSE · NOV 17

Structure Therapeutics develops oral small molecule drugs that target G protein coupled receptors to treat chronic diseases, mainly obesity. It last closed at $18.17 on Nov 17, down 2.15% on the day. In the past 30 days there were 1 dark pool print totaling $500K, the largest $500K.

AI Auto Pilots
Is GPCR in one of our four AI portfolios? Sign in free to see

Key Stats

Last 12 months
Results
Net income
−$293.9M
EPS (diluted)
−$1.30
Free cash flow
−$277.3M
Valuation
Market cap
$3.9B
214.8M shares
P/E
–
No P/E while losing money
Dividend yield
None
No dividend in 12 months
Balance sheet
Cash & equivalents
$222.0M
At Sep 30
Shareholder equity
$1.2B
Shares outstanding
214.8M
At Oct 31
Fiscal year endsDecember
ExchangeNasdaq
Financials history
FY2022: −$51.3M−$51.3MFY2022FY2023: −$89.6M−$89.6MFY2023FY2024: −$122.5M−$122.5MFY2024FY2025: −$141.2M−$141.2MFY2025

From GPCR's SEC filings, latest 10-Q for the period ending Sep 30, 2026 (filed Nov 9). Last 12 months adds up the four latest quarters.

Next report
—
No date on the calendar yet
Consensus EPS forecast
—
 
Year-ago EPS
—
Not on file
Options-implied move
—
 
Analyst consensus
—
No ratings in 90 days
Loading…

Analyst Ratings & Price Targets

Analyst Ratings →
Consensus · 90 days
No firm has rated GPCR in the past 90 days.
Average 12-month target
No price targets on GPCR in the past 90 days.
Latest rating changes
CitigroupMaintained
Aug 7Buy$97
CitizensMaintained
Aug 7Buy$110
HC Wainwright & Co.Maintained
Jun 11Buy$70
Canaccord GenuityInitiated
Apr 27Buy$101
DateFirmActionRatingPrice target
Aug 7CitigroupMaintainedBuy$97
Aug 7CitizensMaintainedBuy$110
Jun 11HC Wainwright & Co.MaintainedBuy$70
Apr 27Canaccord GenuityInitiatedBuy$101
Loading…

Technical Analysis

GPCR · as of the Nov 17 close · updated after every close
Downtrend, oversold

The stock is 14% below its 20 day and 48% below its 50 day average. It is 147% below its 200 day average, so the longer trend is down. Momentum is weak (RSI 28), oversold. The nearest support is the 52 week low at $17.86, and the nearest resistance the Pivot at $18.23.

Short trendBearish
Long trendBearish
MomentumWeak
StretchOversold
VolatilityHigh, 8.1%/day
Key levels
$94.9052 week high+422.3%
$44.90200 day average+147.1%
$38.69100 day average+112.9%
$26.8750 day average+47.9%
$22.36Swing high (Oct 30)+23.1%
$20.7220 day average+14.0%
$18.59Pivot R1+2.3%
$18.23Pivot+0.3%
$18.17Last close
$17.8652 week low−1.7%
$17.80Pivot S1−2.0%
Indicators
RSI (14)27.56Oversold below 30Oversold
MACD-2.15Above its signal lineBullish
Stochastic14.4Near the bottom of its rangeOversold
ADX (14)52.8Strong downtrend
Williams %R-93.6Oversold below −80, overbought above −20Oversold
CCI (20)-198.4Oversold below −100, overbought above 100Oversold
Rate of change−10.7%Change over 10 sessionsBearish
ATR (14)$1.47Typical daily range, 8.1% of price
MA 10Below
MA 20Below
MA 50Below
MA 100Below
MA 200Below
What happened before, for GPCR

What happened before

See how GPCR did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record.

November seasonalityHow GPCR usually does this month. See Seasonality

Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.

Seasonality

How GPCR has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2023.

Loading…

See the stocks that usually rise in November →

Whale Options Flow

90D

No whale options trades in GPCR in the last 90 days.

Loading…

See today’s whale options flow across the market →

Dark Pool

30D
Prints
1
Notional
$500K
Largest print
$500K
Loading…

GPCR Institutional Ownership

Full report →
Fund sentiment · Q3 2026
Bearish
Strongly bearishNeutralStrongly bullish
  • ▼75 buying vs 106 selling
  • ●Held by funds +0.2 pts
  • ▼Funds holding -23
  • ●Superinvestors: 1 added, 1 cut
  • ●Put/call not meaningful
Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Funds holdingHeld by funds %
Q3 2026This quarterLast quarterChange
Funds holding171194−11.9%
In funds' top 1028−75.0%
Held by funds31.6%31.5%+0.2 pts
New / increased26 / 4929 / 76−28.6%
Reduced / sold out61 / 4549 / 34+27.7%
Put/call ratio0.010.00–
Top holders, biggest buyers and sellers, 8 quarters of charts and this season's filings so far.See GPCR institutional ownership →

From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.

AI Auto Pilots

Paper trading

StreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether GPCR is in one of them and how their past GPCR trades turned out.

GPCR in the AI portfolios
Loading…

Macro & Market News

All StreetAlpha news →

StreetAlpha hasn't covered GPCR in an article yet. Here's the latest on the wider market.

GPCR Congress Trades

All congress trades →
Trades, 12 months
0
Buys
0
Sells
0
People
0
Last filed Nov 2
Who traded GPCR · since 2023
Latest 1 filing
$1K – $15KTraded Oct 4, 2023Filed Nov 2, 2023
PersonTypeAmountTradedFiledDelay
Tom CarperD · DESell$1K – $15KOct 4, 2023Nov 2, 202329 d

Members of Congress and senior officials report trades up to 45 days later, as dollar ranges. Filings show a trade happened, not why. Not investment advice.

About Structure Therapeutics

Structure Therapeutics is a biopharmaceutical company based in South San Francisco, California. It is developing oral small molecule drugs that act on G protein coupled receptors, a family of receptors that control many body processes. Its most advanced candidate is aimed at obesity, and its pipeline includes other candidates for metabolic and related conditions. The company is still in clinical development, and its medicines are intended for patients with chronic diseases.

Headquarters
South San Francisco, CA